nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—OPRK1—Progesterone—uterine cancer	0.742	0.807	CbGbCtD
Methylnaltrexone—CYP2D6—Progesterone—uterine cancer	0.136	0.148	CbGbCtD
Methylnaltrexone—CYP2D6—Doxorubicin—uterine cancer	0.0414	0.045	CbGbCtD
Methylnaltrexone—Redness—Progesterone—uterine cancer	0.00607	0.0753	CcSEcCtD
Methylnaltrexone—Injection site reaction—Medroxyprogesterone Acetate—uterine cancer	0.00369	0.0458	CcSEcCtD
Methylnaltrexone—Pain—Carboplatin—uterine cancer	0.00238	0.0295	CcSEcCtD
Methylnaltrexone—Erythema—Progesterone—uterine cancer	0.00179	0.0222	CcSEcCtD
Methylnaltrexone—Flatulence—Progesterone—uterine cancer	0.00176	0.0219	CcSEcCtD
Methylnaltrexone—Redness—Epirubicin—uterine cancer	0.00174	0.0216	CcSEcCtD
Methylnaltrexone—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.0201	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—uterine cancer	0.00161	0.02	CcSEcCtD
Methylnaltrexone—Flatulence—Medroxyprogesterone Acetate—uterine cancer	0.0016	0.0198	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00151	0.0188	CcSEcCtD
Methylnaltrexone—Oedema—Progesterone—uterine cancer	0.00146	0.0181	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—uterine cancer	0.00145	0.018	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Progesterone—uterine cancer	0.00143	0.0178	CcSEcCtD
Methylnaltrexone—Skin disorder—Progesterone—uterine cancer	0.00142	0.0176	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Progesterone—uterine cancer	0.00141	0.0175	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.017	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—uterine cancer	0.00134	0.0166	CcSEcCtD
Methylnaltrexone—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.0164	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.0161	CcSEcCtD
Methylnaltrexone—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00129	0.016	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00128	0.0159	CcSEcCtD
Methylnaltrexone—Erythema—Dactinomycin—uterine cancer	0.00127	0.0157	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Progesterone—uterine cancer	0.00126	0.0157	CcSEcCtD
Methylnaltrexone—Pain—Progesterone—uterine cancer	0.00125	0.0155	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Progesterone—uterine cancer	0.0012	0.0148	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—uterine cancer	0.00117	0.0145	CcSEcCtD
Methylnaltrexone—Abdominal pain—Progesterone—uterine cancer	0.00116	0.0143	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.0142	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.0134	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—uterine cancer	0.00108	0.0134	CcSEcCtD
Methylnaltrexone—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.013	CcSEcCtD
Methylnaltrexone—Oedema—Dactinomycin—uterine cancer	0.00103	0.0128	CcSEcCtD
Methylnaltrexone—Diarrhoea—Progesterone—uterine cancer	0.001	0.0124	CcSEcCtD
Methylnaltrexone—Dizziness—Progesterone—uterine cancer	0.000967	0.012	CcSEcCtD
Methylnaltrexone—Vomiting—Progesterone—uterine cancer	0.000929	0.0115	CcSEcCtD
Methylnaltrexone—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000906	0.0112	CcSEcCtD
Methylnaltrexone—Pain—Dactinomycin—uterine cancer	0.000883	0.011	CcSEcCtD
Methylnaltrexone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000876	0.0109	CcSEcCtD
Methylnaltrexone—Nausea—Progesterone—uterine cancer	0.000868	0.0108	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000845	0.0105	CcSEcCtD
Methylnaltrexone—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000842	0.0104	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dactinomycin—uterine cancer	0.000817	0.0101	CcSEcCtD
Methylnaltrexone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000787	0.00976	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000775	0.00961	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—uterine cancer	0.000726	0.00901	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—uterine cancer	0.000723	0.00897	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dactinomycin—uterine cancer	0.000707	0.00877	CcSEcCtD
Methylnaltrexone—Vomiting—Dactinomycin—uterine cancer	0.000657	0.00815	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—uterine cancer	0.000646	0.00801	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—uterine cancer	0.000639	0.00793	CcSEcCtD
Methylnaltrexone—Nausea—Dactinomycin—uterine cancer	0.000614	0.00761	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—uterine cancer	0.000611	0.00759	CcSEcCtD
Methylnaltrexone—Abdominal pain—Etoposide—uterine cancer	0.000591	0.00733	CcSEcCtD
Methylnaltrexone—Naloxone—ESR1—uterine cancer	0.000587	1	CrCbGaD
Methylnaltrexone—Erythema—Epirubicin—uterine cancer	0.000514	0.00637	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—uterine cancer	0.000512	0.00635	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—uterine cancer	0.000506	0.00628	CcSEcCtD
Methylnaltrexone—Dizziness—Etoposide—uterine cancer	0.000494	0.00613	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—uterine cancer	0.000475	0.0059	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—uterine cancer	0.000475	0.0059	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—uterine cancer	0.000468	0.00581	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—uterine cancer	0.000444	0.00551	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000434	0.00539	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—uterine cancer	0.000419	0.0052	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—uterine cancer	0.000411	0.0051	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—uterine cancer	0.000407	0.00505	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—uterine cancer	0.000405	0.00503	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000402	0.00498	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—uterine cancer	0.000388	0.00481	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—uterine cancer	0.00038	0.00472	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—uterine cancer	0.000377	0.00467	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—uterine cancer	0.000375	0.00465	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000362	0.00449	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—uterine cancer	0.000358	0.00445	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—uterine cancer	0.000343	0.00425	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000335	0.00415	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—uterine cancer	0.000332	0.00411	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—uterine cancer	0.000331	0.00411	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000317	0.00393	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—uterine cancer	0.000307	0.0038	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—uterine cancer	0.000287	0.00356	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—uterine cancer	0.000277	0.00344	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—uterine cancer	0.000266	0.00331	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—uterine cancer	0.000265	0.00329	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—uterine cancer	0.000256	0.00318	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—uterine cancer	0.000249	0.00309	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—uterine cancer	0.000247	0.00306	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—uterine cancer	0.00023	0.00286	CcSEcCtD
